關于箕星<\/b><\/p> \n
箕星是一家總部位于中國上海的生物制藥公司，致力于將創新科學和藥物帶給罹患嚴重危及生命健康疾病的中國患者。箕星由RTW Investments, LP于2019年投資創立，與全球多家生物技術公司開展合作，通過開發和商業化獨特創新的治療藥物，應對心血管和眼科疾病領域尚未滿足的醫療需求。憑借強勁且不斷壯大的產品管線、經驗豐富的管理團隊和以患者為中心的理念，箕星將為大中華地區的患者群體帶來持久而深遠的影響。<\/p> \n
關于<\/b>Milestone Pharmaceuticals<\/b><\/p> \n
Milestone Pharmaceuticals（納斯達克股票代碼：MIST）是一家專注于心血管創新藥物開發及商業化的生物制藥公司。Milestone的主要在研產品etripamil目前正處于治療陣發性室上性心動過速(PSVT) 的 3 期臨床階段和治療快速心室率房顫（ AFib-RVR ）患者的 2 期概念驗證試驗。Milestone Pharmaceuticals在加拿大和美國開展業務。如需了解更多信息，請訪問www.milestonepharma.com<\/a>。<\/p> \n 參考文獻<\/i><\/span><\/p> <\/td> \n <\/tr> \n 1. <\/i>Chiang JK, Kao HH, Kao YH. Association of Paroxysmal Supraventricular Tachycardia with Ischemic Stroke: A National Case-Control Study. <\/i>Journal of Stroke and Cerebrovascular Diseases (2017); 26(7):1493-1499.<\/i><\/span><\/p> <\/td> \n <\/tr> \n 2. <\/i>Chan CL, Li AA, Chung HA, Phan DV. Cost Effectiveness Analysis and Payment Policy Recommendation-Population-Based Survey with Big Data Methodology for Readmission Prevention of Patients with Paroxysmal Supraventricular Tachycardia treated with Radiofrequency Catheter Ablation. <\/i>International Journal of Environmental Research and Public Health (2020); 17(7):2334.<\/i><\/span><\/p> <\/td> \n <\/tr> \n 3. <\/i>Ho HH, Yeh SJ, Tsai WP, et al. Paroxysmal supraventricular tachycardia and Wolff-Parkinson-White syndrome in ankylosing spondylitis: a large cohort observation study and literature review. <\/i>Seminars in Arthritis and Rheumatism (2012); 42(3):246-53.<\/i><\/span><\/p> <\/td> \n <\/tr> \n 4. <\/i>Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. <\/i>Journal of the American College of Cardiology (1998); 31(1):150-7. <\/i><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n <\/p> \n 媒體聯絡<\/i><\/p> \n 箕星藥業 \n \n
\n \n \n \n \n
<\/i>media@jixingbio.com<\/a><\/i> <\/p>"];
$("#dvExtra").html(content_array[0]);})();